The Hidden Threat of RSV in Older Adults
Respiratory syncytial virus, or RSV, is widely recognised as a leading cause of hospitalisation in infants and young children. Yet what many people do not realise is that RSV poses an equally serious β and often underestimated β threat to adults aged 50 and over. Each year, RSV is responsible for tens of thousands of hospitalisations and thousands of deaths among older adults in the developed world alone, with the burden disproportionately affecting those with underlying conditions such as chronic obstructive pulmonary disease (COPD), asthma, heart failure, and diabetes.
Unlike influenza, for which seasonal vaccination has become routine, RSV has until recently lacked an approved vaccine for adult populations. This gap in the prevention landscape has left millions of older adults vulnerable to a virus that can trigger severe lower respiratory tract infections, pneumonia, exacerbation of chronic conditions, and prolonged hospital stays.
Understanding RSV: Why It Matters After 50
RSV is a highly contagious virus that spreads through respiratory droplets and contaminated surfaces. While healthy younger adults typically experience RSV as a common cold, the ageing immune system β a phenomenon known as immunosenescence β means that adults over 50 are significantly less equipped to mount an effective response. The decline in T-cell function, reduced mucosal immunity, and chronic low-grade inflammation that accompany ageing all contribute to increased susceptibility to severe RSV disease.
The consequences are significant. Studies have shown that:
- RSV accounts for approximately 177,000 hospitalisations annually among adults 65 and older in the United States alone.
- The case fatality rate for RSV-hospitalised older adults is estimated at 6β10%, comparable to or exceeding that of seasonal influenza.
- Healthcare costs associated with RSV in older adults run into billions of dollars annually, placing a substantial burden on health systems worldwide.
- Post-infection decline: Many older adults who survive severe RSV experience lasting reductions in lung function and quality of life, with some never fully returning to their pre-infection baseline.
GSKβs Commitment to RSV Prevention
GSK has been at the forefront of the effort to develop effective RSV vaccines for older adults. The companyβs RSV vaccine programme represents years of dedicated research into the virusβs biology and the unique challenges of immunising ageing populations. By targeting the pre-fusion form of the RSV F protein β the conformation most vulnerable to neutralising antibodies β GSKβs approach is designed to generate a robust and durable immune response.
Clinical trials have demonstrated strong efficacy in preventing RSV-associated lower respiratory tract disease in adults aged 60 and over, with a favourable safety profile maintained across multiple RSV seasons. The vaccine has shown particular promise in reducing the most severe manifestations of disease, including those requiring hospitalisation and intensive care.
Overcoming Awareness Barriers
Despite the clinical evidence, awareness of RSV as a threat to older adults remains surprisingly low. Surveys consistently show that while most people are familiar with RSV in the context of infant health, fewer than one in five adults over 50 can identify RSV as a risk to their own age group. This knowledge gap represents a critical barrier to prevention.
Healthcare professionals play a vital role in bridging this gap. By proactively discussing RSV risk during routine consultations, particularly with patients who have chronic respiratory or cardiovascular conditions, clinicians can help ensure that eligible adults are aware of and have access to vaccination. Public health campaigns that normalise RSV vaccination alongside annual flu and COVID-19 boosters are also essential to driving uptake.
Taking Action: What Adults Over 50 Should Know
The message is clear: RSV is not just a childhood illness. Adults over 50, especially those with underlying health conditions, should speak to their healthcare provider about their risk and the available prevention options. As GSK continues to work with health authorities around the world to broaden access to RSV vaccination, the goal is simple but ambitious β to ensure that no older adult is left unprotected against a preventable disease.
Prevention is always better than treatment, and with effective vaccines now within reach, the time for adults over 50 to act is now. Together, we can get ahead of RSV.